Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Evaluate Efficacy and Safety of Fentanyl TAIFUN Treatment after Titrated Dose Administration for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy.

Trial Profile

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Evaluate Efficacy and Safety of Fentanyl TAIFUN Treatment after Titrated Dose Administration for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FINDE
  • Sponsors Akela Pharma

Most Recent Events

  • 07 Sep 2024 The trial has been completed in Hungary, according to European Clinical Trials Database record.
  • 12 Aug 2023 This trial has been completed in Czech republic
  • 18 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top